![SK bioscience CEO Ahn Jae-yong, second from left, speaks during the Regionalised Vaccine Manufacturing Collaborative event held on Monday in Geneva, Switzerland. [SK BIOSCIENCE]](https://koreajoongangdaily.joins.com/data/photo/2023/05/23/b09c9769-9dc6-4118-a4bf-eae338c709eb.jpg)
SK bioscience introduced its “glocalization” project aimed at ensuring equitable access to vaccines, during the Regionalised Vaccine Manufacturing Collaborative (RVMC) in Switzerland, the pharmaceutical company said Tuesday.
The RVMC is an international framework kicked off during the World Economic Forum in Davos in May last year, with the goal of resolving inequality in the vaccine supply.
Ahn Jae-yong, SK bioscience CEO, introduced the company’s glocalization project, which is one of the company’s new business strategies. The project aims to establish local production facilities in regions with limited accessibility to vaccines, by transferring production capabilities, technologies and expertise to local authorities or companies.
The RVMC event was held in Geneva, Switzerland, during the 76th World Health Assembly, which runs from Sunday, May 21 to May 30.
BY SHIN HA-NEE [shin.hanee@joongang.co.kr]
